The purified antagonist may then be combined with compatible, nontoxic pharmaceutical excipients and administered to an animal, e.g. to treat a condition characterized by an excessive growth rate. (The term animal is intended to include humans.) In the case of administration to nonhuman animals, it may be preferable to incorporate the drug into the animal's feed, possibly in a prepared combinati